Literature DB >> 2111957

Expression and characterization of a functional human immunodeficiency virus envelope glycoprotein in insect cells.

D E Wells1, R W Compans.   

Abstract

Recombinant baculoviruses were used to express the gp160 envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) and a truncated variant designated gp160(t) which lacks a transmembrane domain. Glycosylation, proteolytic cleavage, secretion, and biological activities of gp160 and gp160(t) 160(t) were studied in Spodoptera frugiperda cells. Both proteins were rapidly glycosylated and initially were found to be totally endo-beta-N-acetyl-D-glucosaminidase H (endo-H) sensitive. However, partial resistance to endo-H was gradually acquired by both molecules. gp160 was found to remain cell-associated, whereas gp160(t) was secreted into the culture medium in large amounts. A fraction of gp160 and gp160(t) appeared to be proteolytically cleaved, and a cleavage product corresponding in size to gp120 was identified in the culture medium. gp160(t) was found to interact specifically with CD4 receptors without any requirement for proteolytic cleavage. The gp160 protein was shown to be expressed on the surface of S. frugiperda cells by direct immunofluorescence. These surface molecules were biologically active, as demonstrated by their ability to induce syncytium formation when cocultivated with HeLa T4 cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111957     DOI: 10.1016/0042-6822(90)90028-p

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  A short sequence in the N-terminal region is required for the trimerization of type XIII collagen and is conserved in other collagenous transmembrane proteins.

Authors:  A Snellman; H Tu; T Väisänen; A P Kvist; P Huhtala; T Pihlajaniemi
Journal:  EMBO J       Date:  2000-10-02       Impact factor: 11.598

2.  Downstream processing of insect cell cultures.

Authors:  A R Bernard; M Lusti-Narasimhan; K M Radford; R S Hale; E Sebille; P Graber
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

3.  The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site.

Authors:  M Ivey-Hoyle; R K Clark; M Rosenberg
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin.

Authors:  Y Morikawa; E Barsov; I Jones
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

5.  Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain.

Authors:  E Fenouillet; I Jones; B Powell; D Schmitt; M P Kieny; J C Gluckman
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

6.  Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera.

Authors:  M M Hulst; D F Westra; G Wensvoort; R J Moormann
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1.

Authors:  S Bour; F Boulerice; M A Wainberg
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

8.  Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding.

Authors:  Y Li; L Luo; N Rasool; C Y Kang
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

9.  Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus.

Authors:  C B Doyle; U Bhattacharyya; K A Kent; J E Stott; I M Jones
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Inhibition of human immunodeficiency virus type 1-induced cell fusion by recombinant human interferons.

Authors:  D E Wells; S Chatterjee; M J Mulligan; R W Compans
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.